With $13 million in new funding in hand, the small bioinformatics company aims to take on Big Pharma and will look to partner with major molecular labs.
Through AI/ML-enabled platform with a biology-first approach, Genialis looks to propel drug development, diagnostics and treatment planning Genialis, a computational precision medicine company unraveling
Debiopharm Innovatoin Fund & Taiwania Capital co-lead financing round for Genialis to propel drug development, diagnostics and treatment planning through AI/ML-enabled platform with a biology-first